Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
LabGenius expands validation of its EVA antibody-discovery platform through a…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Pfizer's HYMPAVZI FDA label expansion | Lucid Diligence Brief
Pfizer’s HYMPAVZI FDA label expansion covers children 6–11 and patients ≥12…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
IDEAYA and Roche Collaboration | Lucid Diligence Brief
IDEAYA and Roche Test IDE892 plus RG6505 in MTAP-Deleted RAS-Mutant PDAC…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…
Lucid Diligence Brief: Gilead To Acquire Tubulis to Expand Oncology ADC Pipeline
Lucid Diligence Brief: Gilead To Acquire Tubulis to Expand Oncology ADC…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…